FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis

IMPORTANCE: The combination of fluorouracil, oxaliplatin, and irinotecan plus bevacizumab (FOLFOXIRI-Bev) is an established and effective first-line chemotherapy regimen for metastatic colorectal cancer. However, resection rates of metastases and overall survival with this schedule have never been s...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:JAMA Oncol
Main Authors: Tomasello, Gianluca, Petrelli, Fausto, Ghidini, Michele, Russo, Alessandro, Passalacqua, Rodolfo, Barni, Sandro
Format: Artigo
Jezik:Inglês
Izdano: American Medical Association 2017
Teme:
Original Investigation
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5824228/
https://ncbi.nlm.nih.gov/pubmed/28542671
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.0278
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki